Prevail Therapeutics Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Prevail Therapeutics Inc. | PRVL - NASDAQ |
$16.00-$18.00 | $17.00 | $15.31 | 7.4 million | 6/20/2019 |
| Morgan Stanley, BofA Merrill Lynch, Cowen | ||||||
Co-Manager(s): Wedbush PacGrow | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-05-24 Terms Added 2019-06-10 | ||||||
Prevail Therapeutics Inc. Quote & Chart - Click for current quote - PRVL
IPO Boutique aggregates information on public companies and private companies, such as "PRVL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Prevail Therapeutics Inc. (adapted from Prevail Therapeutics Inc. prospectus):
They are a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PRVL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.